rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Vistagen Therapeutics, Inc.

VTGN · Nasdaq

Health CareBiotechnologyNot moving yet

VTGN stood above a rising 150-day average in 7 of the last 52 weekly readings, and has been out of that trend for the last 45 weeks. It is 53.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 45
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
45 (-7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 7 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders45-7 on the quarter
New · exited10 · 16
Reported value$2.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Commodore Capital LPnew · filed 14 Aug 20262,788,620$630K+2,788,620
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 20261,574,200$356K00.0%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026847,992$192K+378,373+80.6%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026730,500$165K+439,200+150.8%
STEMPOINT CAPITAL LPunchanged · filed 14 Aug 2026616,749$17K00.0%
Ikarian Capital, LLCunchanged · filed 14 Aug 2026519,077$117K00.0%
AdvisorShares Investments LLCadded · filed 11 Aug 2026438,643$99K+161,533+58.3%
LUMINUS MANAGEMENT LLCadded · filed 14 Aug 2026403,115$91K+7,062+1.8%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026365,002$83K-88,389−19.5%
ADAR1 Capital Management, LLCreduced · filed 14 Aug 2026351,141$79K-400,000−53.3%
30 Jun 2023 – 30 Jun 2026
274154Jun 23Mar 24Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Douglas J. Williamson Company insiderDirector · last 29 Jul 20260 · 0
Nick B. Tressler Company insiderChief Financial Officer · last 30 Jun 20260 · 0
Reid G. Adler Company insiderChief Legal Officer · last 30 Jun 20261 · 0
Shawn Singh Company insiderPresident and CEO · last 30 Jun 20261 · 0
Angel S. Angelov Company insiderChief Medical Officer · last 18 May 20260 · 0
Elissa S. Cote Company insiderChief Corp Development Officer · last 7 Apr 20260 · 0
Joshua S. Prince Company insiderChief Operating Officer · last 7 Apr 20260 · 0
Paul R. Edick Company insiderDirector · last 27 Oct 20250 · 0
Ann Michelle Cunningham Company insiderDirector · last 9 Sep 20250 · 0
Joanne Curley Company insiderDirector · last 9 Sep 20250 · 0
Jon S. Saxe Company insiderDirector · last 9 Sep 20253 · 0
Margaret M. FitzPatrick Company insiderDirector · last 9 Sep 20250 · 0

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2026 · to 12 Jun 20267.8%
Cash and equivalentsFY 2026 · to 31 Mar 2026$30.8M

Analyst forecasts

No analyst forecasts yet.